Identification of angiotensin I-converting enzyme inhibitory peptides derived from salmon muscle and their antihypertensive effect

• Published in: Fisheries science Vol. 74; no. 4; pp. 911 - 920
• Main Authors: Enari, H.(Nichiro Corp., Kawasaki, Kanagawa (Japan). Central Research Lab.), Takahashi, Y, Kawarasaki, M, Tada, M, Tatsuta, K
• Format: Journal Article
• Language: English
• Published: Tokyo Springer-Verlag 01.08.2008; Blackwell Publishing Asia; Springer Nature B.V
• Subjects: ANGIOTENSIN; angiotensin I-converting enzyme inhibitory activity; ANGIOTENSINA; ANGIOTENSINE; antihypertension; antihypertensive effect; Antihypertensives; Bioassays; Biomedical and Life Sciences; Blood pressure; Body weight; CARDIOVASCULAR AGENTS; chromatography; digestive resistance; ENZYME INHIBITORS; Enzymes; Fish & Wildlife Biology & Management; Food Science; Freshwater & Marine Ecology; HYDROLYSAT DE PROTEINES; HYDROLYZED PROTEINS; Hypertension; IDENTIFICACION; IDENTIFICATION; Ile-Trp; in vitro studies; Ingestion; INHIBIDORES DE ENZIMAS; INHIBITEUR D'ENZYME; inhibitory concentration 50; Intravenous administration; intravenous injection; Life Sciences; MEDICAMENTOS CARDIOVASCULARES; MODIFICATEUR CARDIOVASCULAIRE; MUSCLE; MUSCLES; MUSCULOS; PEPTIDE; PEPTIDES; PEPTIDOS; peptidyl-dipeptidase A; PROTEINAS HIDROLIZADAS; rats; Rodents; SALMON; salmon peptide; Salmonidae; SAUMON; systolic blood pressure; tripeptides; Ile-Trp; angiotensin I-converting enzyme inhibitory activity; antihypertension; salmon peptide; digestive resistance
• ISSN: 0919-9268; 1444-2906
• DOI: 10.1111/j.1444-2906.2008.01606.x

The salmon peptide digested from salmon muscle showed a strong inhibitory activity against the angiotensin I-converting enzyme (ACE). The antihypertensive effect of the salmon peptide on spontaneously hypertensive rats (SHR) was examined. After the single intravenous administration of the salmon peptide at a dose of 30 mg/kg body weight, the systolic blood pressure (SBP) was significantly reduced against the control. Further, a double-blind, placebo-controlled, parallel-group study determined the efficacy of the salmon peptide in mild hypertensive subjects. The SBP, after a 1.0 g of salmon peptide intake, was significantly reduced at 4 weeks after the intake, and 2 weeks after the intake finished, compared to the value before ingestion. Bioassay-guided separation of the salmon peptide, using a combination of column chromatographic techniques, led to the identification of 20 active di- and tri-peptides, including Ile-Val-Phe and Phe-Ile-Ala as two new ACE inhibitory tripeptides. Ile-Trp had the strongest ACE inhibitory activity. (IC 50 =1.2μM) in vitro , and contributed 5.2% to the total ACE inhibitory activity. The salmon peptide and Ile-Trp showed a digestive resistance by in vitro assay, which mimicked the digestive organ, and had no affinity for factors related to blood pressure regulation, except for the ACE inhibitory activity.